Fig. 7: Confocal and inhibitor assays for LPS-induced CD14/LBP pathway in AMs. | Mucosal Immunology

Fig. 7: Confocal and inhibitor assays for LPS-induced CD14/LBP pathway in AMs.

From: Regulatory role of Gpr84 in the switch of alveolar macrophages from CD11blo to CD11bhi status during lung injury process

Fig. 7

a–c Confocal assays for phosphorylated levels of Akt, Erk1/2, and STAT3 in Gpr84+/+ and Gpr84−/− AMs under LPS challenge; d Effects of signal protein inhibitors on the CD14 expression and LBP release in primary AMs, including PI3K (LY294002), Akt (GSK2141795), STAT1 (Fludarabine), STAT3 (S3I201), NF-κB (JSH-23), Erk1/2 (GDC0994), and p38 MAPK (SB203580) (section symbol indicates (§) compared with PBS group, hash symbol indicates (#) compared with DMSO group, asterisk symbol indicates (*) compared with LPS + DMSO group). Data of d are shown as means ± SEM (four biological repeats, two technical repeats), *0.01 < P < 0.05; **P < 0.01; ***P < 0.001.

Back to article page